Topiramate in the Treatment of Pathological Gambling

Status Terminated

Clinical Trial Summary

This study will assess the efficacy of topiramate in the treatment of pathological gambling. Pathological gambling (PG) is a debilitating disorder, generally leading to severe personal, familial, financial, social, and occupational impairments. In PG, the patient experiences a progressive inability to resist impulses to gamble, and gambling significantly disrupt the patient's functioning in the personal, familial, and/or vocational spheres. Topiramate has shown preliminary evidence of efficacy in some impulse control disorders.

Clinical Trial Description

This is a 14-week, outpatient, multicenter, randomized, double-blind, placebo-controlled, flexible-dose study of topiramate in subjects with pathological gambling. After giving informed consent, subjects who meet all the inclusion and exclusion criteria may be enrolled. The study will consist of three phases:

- Washout/Screening Phase (up to 28 days prior to randomization or longer for those medications requiring a longer washout period;

- Double-Blind Phase (Titration: up to 6 weeks; Maintenance: 8 weeks); and

- Taper Phase (approximately 1 week).

The study medication will be titrated to 300 mg/day or the subject's maximum tolerated dose (MTD). Subjects must reach a minimum dose of 50 mg/day by Week 2. The taper phase will last approximately one week where subjects gradually reduce their medication until they are no longer taking study medication.

Patient may also give an optional blood sample for pharmacogenomic testing ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00245583
Study type	Interventional
Source	Icahn School of Medicine at Mount Sinai
Contact
Status	Terminated
Phase	Phase 3
Start date	October 2005
Completion date	May 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02590211` - Poker, Skills and Associated Problems	N/A
Completed	`NCT02203786` - D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement	Phase 2
Completed	`NCT05051085` - Feasibility of the Internet-delivered Treatment "SpilleFri" for Patients With Pathological Gambling	N/A
Completed	`NCT01215357` - Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble	Phase 2
Completed	`NCT04842461` - Mental Health, Addictions and Biomarkers in High Athletes Performance
Not yet recruiting	`NCT03280966` - Effects of Intranasal Naloxone on Gambling Urges in Gambling Disorder	Phase 2
Active, not recruiting	`NCT01743092` - Testing Resources: Manual and Webinar Guided Treatment vs. Manual Guided Treatment	N/A
Active, not recruiting	`NCT01528982` - Susceptibility to Pathological Gambling	N/A
Terminated	`NCT00211822` - Functional Magnetic Resonance Imaging (fMRI) Studies in Pathological Gambling (PG) and Obsessive-Compulsive Disorder (OCD)	N/A
Completed	`NCT01381250` - Effects of Internet-based Treatment of Pathological Gambling	N/A
Completed	`NCT05506384` - Treatment Study for Problematic Gaming and Gambling	N/A
Enrolling by invitation	`NCT03464838` - Effects of Transcranial Direct Current Stimulation (tDCS) in Gambling Disorder	N/A
Terminated	`NCT01560351` - Repeated Low-frequency Transcranial Magnetic Stimulation Reduces Cue-induced Craving: a Randomized, Prospective, Double-blind, Sham-controlled, Cross-over Study	N/A
Completed	`NCT00580567` - Impulsivity in Pathological Gambling	N/A
Completed	`NCT02240485` - Integrative Couple Treatment for Pathological Gambling	N/A
Withdrawn	`NCT01340274` - Community Reinforcement Approach and Family Training (CRAFT) for Problem Gambling	Phase 2
Recruiting	`NCT02491996` - The Efficacy of Therapy Focused on Desire-satisfaction for Disordered Gamblers	N/A
Recruiting	`NCT01154712` - Deep Low-Frequency Repetitive Transcranial Magnetic Stimulation for Cessation of Pathological Gambling	Phase 1
Completed	`NCT00927563` - Tolcapone Treatment of Pathological Gambling	Phase 2
Completed	`NCT01843699` - Topiramate Trial for Pathological Gamblers	Phase 2